Therapy Areas: Inflammatory Diseases
Amgen to acquire ChemoCentryx
5 August 2022 -

US-based Amgen (NASDAQ: AMGN) and ChemoCentryx, Inc., (NASDAQ: CCXI) announced on Thursday that they have entered into a definitive agreement under which Amgen is acquiring ChemoCentryx.

The deal is valued at USD52 per share in cash, indicating an enterprise value of around USD3.7bn.

The financial advisor to Amgen in the transaction is PJT Partners, while Wachtell, Lipton, Rosen & Katz is serving as legal advisor. The financial advisor to ChemoCentryx is Goldman Sachs & Co. LLC, and Latham & Watkins LLP is serving as its legal advisor.

Both the companies' board of directors have unanimously approved the deal, which is subject to ChemoCentryx stockholder approval, regulatory approvals and other customary closing conditions. The transaction is likely to be completed in the fourth quarter of 2022.

Robert A Bradway, chairman and chief executive officer at Amgen, said, 'The acquisition of ChemoCentryx represents a compelling opportunity for Amgen to add to our decades-long leadership in inflammation and nephrology with TAVNEOS, a transformative, first-in-class treatment for ANCA-associated vasculitis.We are excited to join in the TAVNEOS launch and help many more patients with this serious and sometimes life-threatening disease for which there remains significant unmet medical need. We also look forward to welcoming the highly skilled team from ChemoCentryx that shares our passion for serving patients suffering from serious diseases.'